tirzepatide surmount 3 SURMOUNT-3 study design This is a phase 3, multicenter, randomized, Tirzepatide after intensive lifestyle intervention

Cognitive Disorders In the 1-year controlled trials of QSYMIA in adults, the proportion of patients who experienced one or more cognitive-related adverse reactions was 5.0% for QSYMIA 7.5 mg/46 mg and 7.6% for QSYMIA 15 mg/92 mg, compared to 1.5% for placebo

These include compounded GLP-1 medications including Semaglutide and Tirzepatide, which have been shown to effectively reduce body weight and lower the risk of type 2 diabetes

No three-week waits to get in

By signaling through GLP-1R expressed in the reward and satiety areas of central nervous system, GLP-1RAs reduce caloric intake and result in 14 kg weight loss on average over several months

MMWR Surveill Summ